| Business Summary | | Pain
Therapeutics,
Inc.
is
developing
a
new
generation
of
opioid
painkillers
with
improved
clinical
benefits.
The
Company
uses
its
technology
to
reformulate
existing
opioid
painkillers
into
new
drugs,
which
it
believes
offer
enhanced
pain
relief,
fewer
adverse
side
effects
and
reduced
tolerance
and
addiction
compared
to
existing
opioid
painkillers.
If
approved
by
the
Food
and
Drug
Administration
(FDA)
the
Company
believes
its
proprietary
drugs
could
replace
many
existing
opioid
painkillers
commonly
used
to
treat
moderate
to
severe
pain.
The
Company
believes
its
products
may
encounter
fewer
clinical
and
regulatory
hurdles
than
new
chemical
entities,
because
they
consist
of
drugs
that,
individually,
are
already
FDA
approved.
The
Company
product
candidates
include
PTI-555:
Oral
Morphine/Low-Dose
Naltrexone,
PTI-501:
Injectable
Morphine/Low-Dose
Naloxone,
PTI-601:
Tramadol/Low-Dose
Naltrexone,
and
PTI-701:
Hydrocodone/Low-Dose
Naltrexone,
and
PTI-801:
Oxycodone/Low-Dose
Naltrexone. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Pain
Therapeutics,
Inc.
is
a
development
stage
company
that
is
developing
a
new
generation
of
opioid
painkillers
by
reformulating
opioid
drugs
to
improve
clinical
results
and
reduce
side
effects.
For
the
six
months
ended
6/01,
the
company
reported
no
revenues.
Net
loss
applicable
to
Common
decreased
78%
to
$5.3
million.
Lower
loss
reflects
the
absence
of
$14.2
million
for
the
beneficial
conversion
of
Preferred
stock. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Remi Barbier, 41 Chairman,
Pres, CEO | $368K | -- | David Johnson, 47 CFO | 203K | $2.8M | Barry Sherman, M.D., 59 Exec.
VP and CMO | 266K | 1.2M | Michael O' Donnell, 42 Sec.,
Director | -- | -- | Edmon Jennings, 54 CCO | 200K | 260K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|